We’re looking forward to the upcoming Genome Editing Therapeutics Summit in Boston! Luca Biasco, PhD, our VP of Translational Biology, will showcase how our innovative delivery strategies are uniquely designed to accommodate diverse cargoes with exceptional editing efficiency. Don’t miss this opportunity to learn more about the advancements shaping the future of genome editing. To join Luca and 120+ other experts across R&D, drug development, and BD, visit https://ter.li/e1vagm. #GETx
Nvelop Therapeutics
生物技术研究
Cambridge,Massachusetts 7,483 位关注者
Unlocking the full potential of genetic medicines.
关于我们
At?Nvelop, we are working to address the complex challenge of effectively delivering?genetic medicines to target cells within the body (in vivo) in order to help treat patients with previously undruggable diseases. Our team is advancing two next-generation delivery platforms, started in the?labs of our scientific co-founders?Dr. David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung formerly of Mass General Hospital. We will use these platforms to build a pipeline of therapeutics internally and to enable strategic partners. We are building a?culture and organization to support this important?mission,?bringing together individuals that thrive in a supportive environment where diverse perspectives and a passion for discovery drive cutting-edge science and breakthrough medicines. Read something that resonates? Reach out to [email protected].
- 网站
-
https://www.nveloptx.com/
Nvelop Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge,Massachusetts
- 类型
- 私人持股
- 创立
- 2022
地点
-
主要
100 Technology Square
US,Massachusetts,Cambridge,02139
Nvelop Therapeutics员工
-
Keith Joung
Lead Translator at Arena BioWorks; Professor of Pathology (on leave 2023-2025) at Harvard Medical School
-
Aravind Asokan
Professor, Duke University; Biotech Founder
-
Jeff Walsh
Biotech Executive and Board Member with 30+ years of company building experience.
-
Daniel Nedelcu
Principal Scientist, Protein Engineering, Targeted Delivery
动态
-
We have exciting news to DLVR! The?New England Venture Capital Association?(NEVCA) has nominated Nvelop for the 2024 NEVY Award: 'Emerging Life Science Company of the Year'. We're honored to be recognized amongst New England's standout companies and innovators, an incredible testament to the hard work of every Nveloper who has driven our mission forward this year. Check out the full announcement here:?https://ow.ly/HLAW50TZrb2 #NEVYs24
-
On Tuesday Luca Biasco, PhD, VP of Translational Biology, will share new in vivo data supporting the particle component interchangeability and multiplex editing abilities of Nvelop’s DLVR-X and DLVR-M platforms at the second Stemness Symposium hosted by The Francis Crick Institute. View the full programme, including details of the keynote lecture being delivered by Nvelop’s SAB member Luigi Naldini MD, PhD here: https://ow.ly/Q3Oy50TXXh7 #Stemness2024
-
Casey Vanderheyden took home first place in our annual Halloween costume competition (for obvious reasons)! Check out the other awesome competitors on our Life at Nvelop Instagram page: https://ow.ly/MoXK50TXhOv. Happy Halloween! ??
T.I.P. or Treat!! Happy Halloween, and happy pipetting! #womeninstem #biotechnology #Halloween #eppendorf Nvelop Therapeutics, Eppendorf
-
Be sure to say hello if you see?Peter Cabeceiras?and Luca Biasco, PhD at La Nuvola this week! ? On Friday, October 25th, Nvelop will deliver an oral presentation at the 31st Annual?European Society of Gene and Cell Therapy?Congress. Showcasing the latest preclinical data on DLVR-M, this presentation will further demonstrate the programmability and in vivo validation of our novel delivery platform. ? Read more:?https://ow.ly/mVfi50TQBHU
-
Are you attending next week’s Alliance for Regenerative Medicine’s 2024 Cell & Gene Meeting on the Mesa? If so, be sure to catch Nvelop’s company presentation led by Senior Director, Corporate Development & Strategy Mansi Shinde, PhD. This presentation will focus on our two modular platforms, DLVR-X and DLVR-M, and how they're uniquely positioned to realize the promise of genetic medicines. Find it on the agenda: https://lnkd.in/eiUpMy4 ? #CGMesa24
-
We're thrilled to unveil the core values thoughtfully curated by a cross-functional team of Nvelopers: Ngaging, Nquisitive, genuiN, and Npactful. The highest priority of this process was ensuring that the outcome reflects how our incredible team shows up each day. Ultimately, these values serve as our internal compass, and the different ways Nvelopers see them in action are inspiring. We're excited to embed them into the fabric of our organization and Nvelop's story. #CoreValues
-
Our team of Nvelopers gathered last month for the first of what will be an annual all-company offsite: ??Nvelopalooza?? It was an incredible day grounded in strategic planning, intriguing scientific case studies, and reflections on the culture we continue to bolster. Launching our core values stood out as a highlight for all; stay tuned for the reveal of the principals guiding how we connect and execute at Nvelop. #Strategy #Teaming #Values
-
Today, Nvelop CSO Melissa Bonner joins Kevin Friedman, Matthew Wilson, and Carolyne Zimmermann at #BioCenturyGrandRounds for a panel discussion moderated by Douglas Williams. The Round will focus on the promise of tissue-specific delivery and evaluate the potential for untold therapeutic opportunities. View the full schedule: https://ow.ly/lUiV50Tk0o0 BioCentury Inc.
-
What better opportunity to introduce our Summer 2024 cohort of co-ops and interns than National Intern Day? Swipe ?? to meet the group DLVRing fresh perspectives and bright ideas to Nvelop. As a team that celebrates curiosity, the chance to expand the next generation’s toolbox and provide hands-on industry experience is a highlight for all. Welcome to Life at Nvelop!